Teleflex Swings to $409M Loss on Goodwill Impairment, Revenue Jumps 19%

TL;DR

**Teleflex's massive goodwill impairment and debt-fueled acquisition make it a risky bet despite revenue growth; steer clear until integration proves profitable.**

AI Summary

Teleflex Inc. (TFX) reported a significant net loss of $408.89 million for the three months ended September 28, 2025, a stark contrast to the net income of $111.00 million in the prior-year period. This loss was primarily driven by a substantial goodwill impairment charge of $403.93 million and restructuring charges of $117.62 million. Despite the net loss, net revenues increased by 19.45% to $913.02 million for the quarter, up from $764.38 million in Q3 2024, largely due to the acquisition of BIOTRONIK SE & Co. KG's Vascular Intervention business. Interventional product revenues surged by 77.77% to $266.41 million. However, Interventional Urology and OEM revenues declined by 14.00% and 2.60% respectively. The company also saw a significant increase in long-term borrowings, rising to $2.57 billion from $1.56 billion at December 31, 2024, to finance the acquisition. Cash provided by operating activities from continuing operations decreased to $188.97 million for the nine months ended September 28, 2025, from $435.62 million in the prior year.

Why It Matters

This filing reveals a critical turning point for Teleflex, as a massive goodwill impairment charge signals potential overvaluation of past acquisitions or a deteriorating outlook for certain business segments, directly impacting investor confidence. The significant increase in debt to finance the BIOTRONIK acquisition, while boosting revenue, introduces higher financial risk and could strain future profitability, affecting employees through potential cost-cutting measures. For customers, the expanded interventional portfolio from the acquisition could offer new solutions, but the underlying financial instability might raise concerns about long-term product support and innovation. Competitors will be watching closely to see if Teleflex can integrate the new business effectively and return to profitability, especially given the competitive landscape in medical devices.

Risk Assessment

Risk Level: high — The risk level is high due to a $403.93 million goodwill impairment charge and $117.62 million in restructuring charges for the three months ended September 28, 2025, indicating significant operational or asset valuation issues. Additionally, long-term borrowings increased by over $1 billion to $2.57 billion from $1.56 billion at December 31, 2024, to finance the BIOTRONIK acquisition, substantially increasing the company's debt burden.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to TFX given the substantial net loss driven by goodwill impairment and increased debt. Monitor the integration of the BIOTRONIK acquisition closely for signs of successful synergy realization and a return to profitability before considering any new investment.

Financial Highlights

revenue

$913.02M

total Debt

$2.57B

net Income

-$408.89M

eps

-$9.24

gross Margin

49.46%

revenue Growth

+19.45%

Revenue Breakdown

Key Numbers

• $408.89M — Net Loss (For Q3 2025, a significant swing from $111.00M net income in Q3 2024.)
• $913.02M — Net Revenues (Increased by 19.45% for Q3 2025 compared to Q3 2024.)
• $403.93M — Goodwill Impairment Charge (Major contributor to the net loss in Q3 2025.)
• $117.62M — Restructuring Charges (Significant increase from $0.29M in Q3 2024, impacting profitability.)
• $266.41M — Interventional Product Revenue (Increased by 77.77% in Q3 2025, driven by the BIOTRONIK acquisition.)
• $2.57B — Long-term Borrowings (Increased from $1.56B at Dec 31, 2024, primarily for the BIOTRONIK acquisition.)
• $825.2M — BIOTRONIK Acquisition Cost (Net initial cash payment for the Vascular Intervention business.)
• $188.97M — Net Cash from Operations (Decreased from $435.62M for the nine months ended Sep 28, 2024.)
• -$9.24 — Diluted EPS (For Q3 2025, a significant drop from $2.36 in Q3 2024.)
• 44,194,408 — Shares Outstanding (As of November 4, 2025.)

Key Players & Entities

• TELEFLEX INCORPORATED (company) — registrant
• BIOTRONIK SE & Co. KG (company) — seller of Vascular Intervention business
• $408,892 (dollar_amount) — Net loss for the three months ended September 28, 2025
• $111,004 (dollar_amount) — Net income for the three months ended September 29, 2024
• $913,021 (dollar_amount) — Net revenues for the three months ended September 28, 2025
• $764,375 (dollar_amount) — Net revenues for the three months ended September 29, 2024
• $403,925 (dollar_amount) — Goodwill impairment charge for the three months ended September 28, 2025
• $117,623 (dollar_amount) — Restructuring charges for the three months ended September 28, 2025
• $825.2 million (dollar_amount) — Net initial cash payment for the VI Business acquisition
• $2,571,504 (dollar_amount) — Long-term borrowings as of September 28, 2025

FAQ

Risk Factors

• Significant Goodwill Impairment [high — financial]: The company recorded a substantial goodwill impairment charge of $403.93 million in Q3 2025, directly contributing to a net loss of $408.89 million. This indicates a potential overvaluation of acquired assets or a significant decline in their expected future performance.
• Increased Debt Load [high — financial]: Long-term borrowings increased significantly to $2.57 billion from $1.56 billion at the end of 2024, primarily to finance the BIOTRONIK acquisition. This substantial increase in debt raises financial leverage and interest expense.
• Restructuring Charges [medium — operational]: The company incurred $117.62 million in restructuring charges in Q3 2025, a sharp increase from $0.29 million in the prior year. These charges negatively impact profitability and suggest ongoing integration or operational adjustments.
• Decreased Operating Cash Flow [medium — financial]: Net cash provided by operating activities for the nine months ended September 28, 2025, decreased to $188.97 million from $435.62 million in the prior year. This reduction in cash generation from core operations is a concern.
• Acquisition Integration Risk [medium — market]: The significant revenue growth in Interventional Products is tied to the BIOTRONIK acquisition. Failure to successfully integrate this business or realize expected synergies could negatively impact future financial performance.
• Segment Revenue Declines [low — market]: Despite overall revenue growth, Interventional Urology and OEM segments experienced revenue declines of 14.00% and 2.60% respectively. This indicates potential weakness in specific product lines or market segments.

Industry Context

The medical device industry is characterized by intense competition, rapid technological advancements, and significant regulatory oversight. Companies like Teleflex compete across various segments, including cardiovascular, urology, and surgical. Recent consolidation, such as Teleflex's acquisition of BIOTRONIK's Vascular Intervention business, highlights a trend towards strategic M&A to gain market share and expand product portfolios.

Regulatory Implications

As a medical device company, Teleflex is subject to stringent regulations from bodies like the FDA. Changes in healthcare policy, reimbursement rates, and increased scrutiny on product safety and efficacy can pose significant risks. The company's ability to navigate these regulatory landscapes is crucial for sustained growth and market access.

What Investors Should Do

1. Monitor integration of BIOTRONIK acquisition
2. Analyze trends in declining segments
3. Assess debt management strategy
4. Evaluate the impact of restructuring and impairment charges

Key Dates

• 2025-09-28: End of Q3 2025 reporting period — Reported a significant net loss of $408.89 million, driven by goodwill impairment and restructuring charges, despite revenue growth.
• 2025-11-04: Shares Outstanding reported — 44,194,408 shares outstanding as of this date.
• 2024-12-31: End of Fiscal Year 2024 — Long-term borrowings stood at $1.56 billion prior to the recent increase.

Glossary

Goodwill Impairment Charge

A non-cash charge taken when the carrying value of goodwill on the balance sheet exceeds its fair value, indicating that the acquired business is not performing as expected. (A major driver of Teleflex's net loss in Q3 2025, totaling $403.93 million.)

Restructuring Charges

Costs associated with significant reorganizations, such as layoffs, facility closures, or integration of acquired businesses. (Increased substantially to $117.62 million in Q3 2025, impacting profitability.)

Continuing Operations

Refers to the ongoing business activities of a company that are expected to continue into the future, as opposed to discontinued operations which have been or will be divested. (Net loss from continuing operations was $408.88 million for Q3 2025.)

Diluted EPS

Earnings per share calculated after accounting for all potential dilutive securities, such as stock options and convertible bonds. (Reported as -$9.24 for Q3 2025, a significant decrease from $2.36 in the prior year.)

Weighted average common shares outstanding

The average number of a company's outstanding shares over a specific period, used in EPS calculations. (Diluted shares outstanding were 47,012 thousand for Q3 2025.)

Year-Over-Year Comparison

Teleflex Inc. reported a dramatic shift from net income of $111.00 million in Q3 2024 to a net loss of $408.89 million in Q3 2025. While net revenues grew by 19.45% to $913.02 million, largely due to acquisitions, this was overshadowed by a $403.93 million goodwill impairment charge and $117.62 million in restructuring costs. Operating cash flow also significantly decreased from $435.62 million to $188.97 million for the nine-month period, indicating a weaker cash generation profile compared to the prior year.

Key Financial Figures

• $1.00 — ich registered Common Stock, par value $1.00 per share TFX New York Stock Exchange

Filing Documents

• tfx-20250928.htm (10-Q) — 1511KB
• tfx-2025928xex311.htm (EX-31.1) — 9KB
• tfx-2025928xex312.htm (EX-31.2) — 10KB
• tfx-2025928xex321.htm (EX-32.1) — 5KB
• tfx-2025928xex322.htm (EX-32.2) — 5KB
• 0000096943-25-000138.txt ( ) — 8794KB
• tfx-20250928.xsd (EX-101.SCH) — 52KB
• tfx-20250928_cal.xml (EX-101.CAL) — 98KB
• tfx-20250928_def.xml (EX-101.DEF) — 311KB
• tfx-20250928_lab.xml (EX-101.LAB) — 685KB
• tfx-20250928_pre.xml (EX-101.PRE) — 524KB
• tfx-20250928_htm.xml (XML) — 1422KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

: Financial Statements (Unaudited)

Item 1: Financial Statements (Unaudited): 2 Condensed Consolidated Statements of Income 2 Condensed Consolidated Statements of Comprehensive Income 3 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Changes in Equity 6 Notes to Condensed Consolidated Financial Statements 7

: Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations 26

: Quantitative and Qualitative Disclosures About Market Risk

Item 3: Quantitative and Qualitative Disclosures About Market Risk 37

: Controls and Procedures

Item 4: Controls and Procedures 37

— OTHER INFORMATION

PART II — OTHER INFORMATION

: Legal Proceedings

Item 1: Legal Proceedings 38

: Risk Factors

Item 1A: Risk Factors 38

: Unregistered Sales of Equity Securities and Use of Proceeds

Item 2: Unregistered Sales of Equity Securities and Use of Proceeds 38

: Defaults Upon Senior Securities

Item 3: Defaults Upon Senior Securities 38

: Mine Safety Disclosures

Item 4: Mine Safety Disclosures 38

: Other Information

Item 5: Other Information 38

: Exhibits

Item 6: Exhibits 40

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements TELEFLEX INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Three Months Ended Nine Months Ended September 28, 2025 September 29, 2024 September 28, 2025 September 29, 2024 (Dollars and shares in thousands, except per share) Net revenues $ 913,021 $ 764,375 $ 2,394,579 $ 2,251,915 Cost of goods sold 461,379 334,203 1,122,413 989,151 Gross profit 451,642 430,172 1,272,166 1,262,764 Selling, general and administrative expenses 281,764 247,257 719,555 740,718 Research and development expenses 57,228 38,726 132,153 117,119 Pension settlement (benefit) charge — ( 5,407 ) — 132,732 Goodwill impairment charge 403,925 — 403,925 — Restructuring charges, separation costs and other impairment charges 117,623 285 144,550 10,799 (Loss) income from continuing operations before interest and taxes ( 408,898 ) 149,311 ( 128,017 ) 261,396 Interest expense 31,841 21,058 72,093 64,909 Interest income ( 2,163 ) ( 2,298 ) ( 5,723 ) ( 5,751 ) (Loss) income from continuing operations before taxes ( 438,576 ) 130,551 ( 194,387 ) 202,238 (Benefit) taxes on (loss) income from continuing operations ( 29,699 ) 19,633 ( 3,198 ) ( 4,586 ) (Loss) income from continuing operations ( 408,877 ) 110,918 ( 191,189 ) 206,824 Operating (loss) income from discontinued operations ( 20 ) 112 ( 157 ) ( 639 ) (Benefit) taxes on operating (loss) income from discontinued operations ( 5 ) 26 ( 36 ) ( 146 ) (Loss) income from discontinued operations ( 15 ) 86 ( 121 ) ( 493 ) Net (loss) income $ ( 408,892 ) $ 111,004 $ ( 191,310 ) $ 206,331 Earnings per share: Basic: (Loss) income from continuing operations $ ( 9.24 ) $ 2.37 $ ( 4.27 ) $ 4.40 Income (loss) from discontinued operations — 0.01 — ( 0.01 ) Net (loss) income $ ( 9.24 ) $ 2.38 $ ( 4.27 ) $ 4.39 Diluted: (Loss) income from continuing operations $ ( 9.24 ) $ 2.36 $ ( 4.27 ) $ 4.38 Loss from discontinued operations — — — ( 0.01 ) Net (loss) income $ ( 9.24 ) $ 2.36 $ ( 4.2

View Full Filing

View this 10-Q filing on SEC EDGAR